BOCA RATON, Fla., Sept. 10, 2013 /PRNewswire/ -- Sensus Healthcare is proud to announce their newest introduction for non-melanoma skin cancer treatment at the 55th annual American Society of Therapeutic Radiation Oncology in Atlanta, GA. on September 22-25, 2013. Visit booth #427 to learn more about the advanced SRT-100™ superficial radiotherapy platform, featuring SharpBeam™ and introducing the recently FDA cleared technology that now allows you to "See what you Treat"! The innovative SRT-100 "VISION" offers unique features and benefits providing major teaching and community hospitals with a cost effective, proven, non-invasive option for treating their patients who are diagnosed with skin cancer!
We cordially invite all ASTRO attendees to visit our booth (#427) at the upcoming 55th Annual ASTRO Meeting in Atlanta, GA. and rediscover superficial radiotherapy (SRT). We are proud to feature our SRT-100™ "VISION" non-invasive treatment system and demonstrate the impact it can have in your community by providing your patients with a non-invasive treatment option while at the same time increasing your productivity and realizing an excellent ROI! "Our latest technology provides so many features and benefits never offered before to Skin Cancer patients. Skin Cancer is a huge epidemic and now Sensus is the 1st to offer a real total solution for Physicians and their Patients," stated Joe Sardano, President/CEO, Sensus Healthcare.
See you in Atlanta!
About Sensus Healthcare:
Sensus Healthcare is the worldwide leader dedicated to Superficial Radiotherapy Technology (SRT). The featured SRT-100 System is the most advanced non-invasive technology used throughout the world in treating Basal Cell (BCC) and Squamous Cell (SCC) Carcinomas. And now with the latest introduction, the SRT-100 "VISION" you can now "SEE what you TREAT"! With over 20,000 patients having been treated, The SRT-100 features SharpBeam technology providing the most accurate and safest treatment possible resulting in proven outcomes. Also the SRT-100 is being used to treat keloids. In conjunction with surgery, the SRT-100 can reduce the recurrences of keloid scarring from 90% to less than 12%. Visit our web site to learn more about Sensus Healthcare!
Taking new Aim at treating Skin Cancer and Keloids! www.sensushealthcare.com
561-922-5808 Ext. 100
SOURCE Sensus Healthcare